Diffusion and Economic Consequences of Health Technologies in Prostate Cancer Care in Sweden, 1991-2002

European Urology

Volumn 49, Issue 6, 2006, Pages 1028-1034

  Sennfält, Karin ^a   Carlsson, Per ^a   Varenhorst, Eberhard ^b  

^a LINKÖPING UNIVERSITY   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Costs; Diffusion; Health technologies; Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; COST EFFECTIVENESS ANALYSIS; DATA BASE; DIFFUSION; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL TECHNOLOGY; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SWEDEN; UNIVERSITY HOSPITAL;

DIFFUSION OF INNOVATION; HUMANS; MALE; PROSTATIC NEOPLASMS; SWEDEN;

EID: 33646380612     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2005.12.018     Document Type: Article

References (26)

1. The National Board of Health and Welfare: Cancer Incidence in Sweden 2003. Stockholm, 2005.
2. Regionalt Onkologiskt Centrum i Uppsala/Örebroregionen: Prostate cancer registration 1998-2002. Uppsala, 2004. Available from www.roc.se.
3. Sennfält K., Carlsson P., Thorfinn J., Frisk J., Henriksson M., and Varenhorst E. Technological changes in the management of prostate cancer result in increased healthcare costs-a retrospective study in a defined Swedish population. Scand J Urol Nephrol 37 (2003) 226-231
4. Ransohoff D.F., McNaughton Collins M., and Fowler F.J. Why is prostate cancer screening so common when the evidence is so uncertain? A system without negative feedback. Am J Med 113 (2002) 663-667
5. Iversen P., Tyrrell C.J., Kaisary A.V., Anderson J.B., Van Poppel H., Tammela T.L.J., et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 164 (2000) 1579-1582
6. Iversen P., Johansson J.-E., Lodding P., Lukkarinen O., Lundmo P., Klarskov P., et al. Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian prostate cancer group. Study number 6. J Urol 172 (2004) 1871-1876
7. Tyrrell C.J., Kaisary A.V., and Iversen P. A randomised comparison of "Casodex" (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 33 (1998) 447
8. Vogelzang N.J., Chodak G.W., Soloway M.S., Block N.L., Schellhammer P.F., Smith J.A., et al. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Urology 46 (1995) 220-226
9. Bill-Axelsson A., Holmberg H., Ruutu M., Häggman M., Andersson S.-O., Bratell S., et al. Radical prostatectomy versus watchful waiting in early prostate cancer. NEJM 352 (2005) 1977-1984
10. Rogers E.M. Diffusion of Innovations (2003), The Free Press, New York
11. Carlsson P. Spridning och ekonomiska effekter av medicinsk teknologi: Institutionen för TEMA. Linköping, Linköping University, 1987.
12. Statistics Sweden.(Accessed at www.scb.se 041125).
13. Sandblom G., Dufmats M., Olsson M., and Varenhorst E. Validity of a population-based cancer register in Sweden an assessment of data reproducibility in the South-East region prostate cancer register. Scand J Urol Nephrol 37 (2003) 112-119
14. State of the Art-Prostatacancer.(Accessed at www.urology.org/sota/STA026/sta026.htm 040907).
15. Potosky A.L., Davis W.W., Hoffman R.M., Stanford J.L., Stephenson R.A., Penson D.F., et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. JNCI 96 (2004) 1358-1367
16. Varenhorst E., Garmo H., Holmberg L., Adolfsson J., Damber J.-E., Hellström M., et al. The National Prostate Cancer Register in Sweden 1998-2002. Trends in Incidence, Treatment and Survival. Scand J Urol Nephrol 39 (2005) 117-123
17. Carlsson P., Hjertberg H., Jönsson B., and Varenhorst E. The cost of prostatic cancer in a defined population. Scand J Urol Nephrol 23 (1989) 93-96
18. Holmberg H., Carlsson P., Kalman D., and Varenhorst E. Impact on health service costs of medical technologies used in management of prostatic cancer. Scand J Urol Nephrol 32 (1998) 195-199
19. Statistics Sweden.(Accessed at www.scb.se 041219).
20. Carlsson P., and Jorgensen T. Scanning the horizon for emerging health technologies. Int J Technol Assess Health Care 14 (1998) 695-704
21. Velden G.H.M. The identification of new health care technologies by the Health Council of the Netherlands. Int J Technol Assess Health Care 14 (1998) 671-679
22. Stevens A., Packer C., and Robert G. Early warning of new health care technologies in the United Kingdom. Int J Technol Assess Health Care 14 (1998) 680-686
23. Jörgensen T., and Larsen L.G. Basis for decisions on emerging health technology. Int J Technol Assess Health Care 14 (1998) 624-635
24. Mowatt G., Thomson M.A., Grimshaw J., and Grant A. Implementing early warning messages on emerging health technologies. Int J Technol Assess Health Care 14 (1998) 663-670
25. Carlsson P., Hultin H., and Törnwall J. The early experiences of a national system for the identification and assessment of emerging health care technologies in Sweden. Int J Technol Assess Health Care 14 (1998) 687-694
26. Aus G., Abbou C.C., Pacik D., Schimd H.P., van Poppel H., and Wolff J.M. EAU guidelines on prostate cancer. Eur Urol 40 (2001) 97-101